A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases

Authors

Callum Ah Docherty, Monash University
Anuruddika J Fernando, University of Edinburgh
Sarah Rosli, Monash University
Maggie Lam, Monash University
Roland E Dolle, Washington University School of Medicine in St. Louis
Manuel A Navia, Hub-Bio Strategic Advising
Ronald Farquhar, Adiso Therapeutics
Danny La France, Adiso Therapeutics
Michelle D Tate, Monash University
Christopher K Murphy, Adiso Therapeutics
Adriano G Rossi, University of Edinburgh
Ashley Mansell, Monash University

Journal

Clinical & Translational Immunology

Publication Date

1-1-2023

Volume

12

Issue

6

First Page

e1455

Document Type

Open Access Publication

DOI

10.1002/cti2.1455

Rights and Permissions

Docherty, C.A., Fernando, A.J., Rosli, S., Lam, M., Dolle, R.E., Navia, M.A., Farquhar, R., La France, D., Tate, M.D., Murphy, C.K., Rossi, A.G. and Mansell, A. (2023), A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clin Transl Immunol, 12: e1455. https://doi.org/10.1002/cti2.1455 © 2023 Adiso Therapeutics and The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Docherty, Callum Ah; Fernando, Anuruddika J; Rosli, Sarah; Lam, Maggie; Dolle, Roland E; Navia, Manuel A; Farquhar, Ronald; La France, Danny; Tate, Michelle D; Murphy, Christopher K; Rossi, Adriano G; and Mansell, Ashley, "A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases." Clinical & Translational Immunology. 12, 6. e1455 (2023).
https://digitalcommons.wustl.edu/oa_4/2929

Additional Links

Supplemental material is available for this article at publisher site.